- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
Pitcairn Co. Trims Bristol Myers Squibb Holdings
Institutional investor reduces stake in pharmaceutical company by 67% in Q3
Published on Mar. 9, 2026
Got story updates? Submit your updates here. ›
Pitcairn Co., an institutional investor, trimmed its holdings in Bristol Myers Squibb Company (NYSE:BMY) by 67.0% in the third quarter, according to a recent SEC filing. The firm now owns 9,984 shares of the biopharmaceutical company's stock, valued at $450,000 as of its latest reporting period.
Why it matters
The reduction in Pitcairn Co.'s Bristol Myers Squibb position reflects broader trends in the pharmaceutical sector, as investors weigh factors like drug pipelines, patent expirations, and market competition. Institutional investors' trading activity can provide insights into sentiment around major industry players.
The details
According to the 13F filing, Pitcairn Co. sold 20,260 shares of Bristol Myers Squibb during the third quarter, leaving it with a remaining stake of 9,984 shares. The firm cited portfolio rebalancing and risk management as reasons for the trimmed position.
- Pitcairn Co. filed its 13F report for the third quarter of 2026.
The players
Pitcairn Co.
An institutional investment firm that manages assets for high-net-worth individuals and families.
Bristol Myers Squibb Company
A global biopharmaceutical company focused on developing and delivering innovative medicines for serious diseases.
The takeaway
The reduction in Pitcairn Co.'s Bristol Myers Squibb holdings reflects the ongoing volatility and competitive dynamics in the pharmaceutical industry, as investors carefully monitor factors like drug pipelines, patent expirations, and market share when making portfolio decisions.
